About this trial
The goal of this clinical study is to evaluate the safety and preliminary efficacy of an investigational umbilical cord blood-derived stem cell and exosome infusion in adults with chronic lower back pain associated with degenerative spine disease. The primary questions this study aims to answer are whether the investigational infusion is safe and well tolerated and whether treatment may reduce pain and improve physical function and quality of life. Researchers will compare the investigational infusion to a placebo (saline solution) to evaluate potential treatment effects in participants with chronic mechanical lower back pain. Participants will receive either the investigational infusion or placebo intravenously during a study visit, complete pain, disability, and quality-of-life assessments, undergo magnetic resonance imaging (MRI) and laboratory testing, and attend follow-up evaluations over a 6-month period. Participants initially assigned to placebo may later receive the investigational treatment during an open-label crossover phase of the study.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18-85 years
Chronic lower back pain ≥3 months
Baseline VAS-Average ≥4/10
Able to comply with study visits and procedures
Disqualifiers
Pregnancy or breastfeeding
Prisoners or decisionally impaired adults
Active malignancy (except non-melanoma skin cancer)
Immunodeficiency or active systemic infection
Trial design
Crossover
Treatments tested in this trial
Umbilical Cord Blood-Derived Stem Cells and Exosomes
Biological/VaccineIntravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes.
Placebo IV
Other interventionMatched placebo intravenous infusion (administered in the same volume and manner as stem cell and exosome product).
Treatment groups
Trial outcomes
Primary outcomes
Change in Average Low Back Pain Intensity From Baseline to Month 3
Measured using the Visual Analog Scale (VAS-Average), a 0-10 scale assessing average low back pain intensity over the past week, with higher scores indicating greater pain severity.
Change in Functional Disability From Baseline to Month 3
Measured using the Oswestry Disability Index (ODI), a validated questionnaire assessing disability related to low back pain, scored from 0-100%, with higher scores indicating greater disability.
Secondary outcomes
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Assessment of safety and tolerability based on the frequency, severity, and relationship of adverse events following investigational infusion, graded using Common Terminology Criteria for Adverse Events (CTCAE v5.0).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.